Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Non-Randomized, Open-Label, Parallel-Group Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Multiple Doses of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function

NCT07694869 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07694869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07694869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Non-Randomized, Open-Label, Parallel-Group Phase I Clinical Trial to Evaluate the Pharmacokinetic Characteristics of Multiple Doses of Ammoxetine Hydrochloride Enteric-Coated Tablets in Participants With Moderate Renal Impairment and Normal Renal Function
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
May 10, 2026
Completion date
November 11, 2026
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy participants, participants with moderate renal impairment